Single-site Versus Multiport Robotic Hysterectomy in Benign Gynecologic Diseases: A Retrospective Evaluation of Surgical Outcomes and Cost AnalysisStefano Bogliolo, Bárbara Gardella, Simone Ferrero et al.|Journal of Minimally Invasive Gynecology|2016Cited by 53
Oxaliplatin for the treatment of ovarian cancerStefano Bogliolo, Arsenio Spinillo, L Babilonti et al.|Expert Opinion on Investigational Drugs|2015Cited by 33
Neoadjuvant Chemotherapy Followed by Radical Surgery versus Concurrent Chemo-Radiotherapy in the Treatment of Locally Advanced Cervical Cancer: A Multicenter Retrospective AnalysisPaolo Sala, Pierangelo Marchiolè, Stefano Bogliolo et al.|Journal of Investigative Surgery|2020Cited by 22
Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).Giovanni Scambia, Domenica Lorusso, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2022Cited by 6
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III TrialDomenica Lorusso, Giovanni Scambia, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2024Cited by 3